Human mesenchymal stromal cells can uptake and release ciprofloxacin, acquiring in vitro anti-bacterial activity

Cytotherapy

Volumn 16, Issue 2, 2014, Pages 181-190

  Sisto, Francesca ^a   Bonomi, Arianna ^a   Cavicchini, Loredana ^a   Coccè, Valentina ^a   Scaltrito, Maria Maddalena ^a   Bondiolotti, Gianpietro ^a   Alessandri, Giulio ^b   Parati, Eugenio ^b   Pessina, Augusto ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Ciprofloxacin; In vitro anti bacterial activity; Mesenchymal stromal cells

Indexed keywords

CIPROFLOXACIN; PACLITAXEL;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BROTH DILUTION; CELL CULTURE; CELL LYSATE; COCULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG UPTAKE; ESCHERICHIA COLI; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MESENCHYMAL STROMA CELL; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

CIPROFLOXACIN; IN VITRO ANTI-BACTERIAL ACTIVITY; MESENCHYMAL STROMAL CELLS;

ANTI-BACTERIAL AGENTS; BLOOD BACTERICIDAL ACTIVITY; BONE AND BONES; CELL- AND TISSUE-BASED THERAPY; CELLS, CULTURED; CHRONIC DISEASE; CIPROFLOXACIN; ENDOCYTOSIS; EXOCYTOSIS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OSTEOMYELITIS;

EID: 84892454476     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.11.009     Document Type: Article

References (38)

1. Wright J.A., Nair S.P. Interaction of staphylococci with bone. Int J Med Microbiol 2010, 300:193-204.
2. Simpson A.H., Deakin M., Lathan J.M. Chronic osteomyelitis: the effect of surgical resection on infection-free survival. JBone Joint Surg Br 2001, 83:403-407.
3. Cierny G., Mader J.T., Penninck J.J. Aclinical staging system for adult osteomyelitis. Clin Orthop 2003, 414:7-24.
4. Nelson C.L., McLaren S.G., Skinner R.A., Smelzer M.S., Thomas J.R., Olsen K.M. The treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium sulfate tobramycin pellets. JOrthop Res 2002, 20:643-647.
5. Holtom P.D., Patzakis M.J. Newer methods of antimicrobial delivery for bone and joint infections. AAOS Instr Course Lect 2003, 52:745-749.
6. Hansen A.D., Osmon D.R., Patel R. Local antibiotic delivery systems: what are and where are we going?. Clin Orthop Relat Res 2005, 437:111-114.
7. Kadry A.A., Al-Suwayeh S.A., Abd-Allah A.R.A., Bayomi M.A. Treatment of experimental osteomyelitis by liposomal antibiotics. JAntimicrob Chemother 2004, 54:1103-1108.
8. Koort J.K., Mäkinen T.J., Suokas E., Veiranto M., Jalava J., Knuuti J., et al. Efficacy of ciprofloxacin releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus. Antimicrob Agents Chemother 2005, 49:1502-1508.
9. Koort J.K., Mäkinen T.J., Suokas E., Veiranto M., Jalava J., Törmala P., et al. Sustained release of ciprofloxacin from an osteoconductive poly(DL)-lactide implant. Acta Orthopaedica 2008, 79:295-301.
10. Kanellakopoulou K., Kolia M., Anastassiadis A., Korakis T., Giamarellos-Bourouliset E.J., Andreopulos A., et al. Lactic acid polymers as biodegradable carriers of fluoroquinolones: an in vitro study. Antimicrob Agents Chemother 1999, 43:714-716.
11. Beardmore A.A., Brooks D.E., Wenke J.C., Thomas D.B. Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute. JBone Joint Surg Am 2005, 87:107-112.
12. Xie Z., Liu X., Zhang C., Huang W., Wang Q. Treatment of osteomyelitis and repair of bone defect by degradable bioactive borate glass releasing vancomycin. JControl Release 2009, 139:118-126.
13. Horst S.A., Hoerr V., Beineke A., Kreis C., Tuchscherr L., Kalinka J., et al. Anovel mouse model of Staphylococcus aureus chronic osteomyelitis that closely mimics the human infection: an integrated view of disease pathogenesis. Am J Pathol 2012, 181:1206-1214.
14. Fukuda M., Yoshitake Y., Sasaki K. The uptake of fluoroquinolone agent drugs by cultured human conjuctival epithelial cells and cultured SIRC rabbit corneal cells. Nihon Ganka Gakkai Zasshi 1999, 103:576-579.
15. Garcia I., Pascual A., Guzman M.C., Perea E.J. Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leucocytes and tissue culture cells. Antimicrob Agents Chemother 1992, 36:1053-1056.
16. Lew D.P., Waldvogel F.A. Quinolones and osteomyelitis: state of- the-art. Drugs 1995, 49(Suppl. 2):101-111.
17. Pessina A., Piccirillo M., Mineo E., Catalani P., Gribaldo L., Marafante E., et al. Role of SR-4987 stromal cells in the modulation of doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (CFU-GM). Life Sci 1999, 65:513-523.
18. Pessina A., Bonomi A., Coccè V., Invernici G., Navone S., Cavicchini L., et al. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS One 2011, 6:e28321.
19. Pessina A., Eletti B., Croera C., Savalli N., Diodovich C., Gribaldo L. Pancreas developing markers expressed on human mononucleated umbilical cord blood. Biochem Biophys Res Commun 2004, 323:315-322.
20. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
21. Reed L.J., Muench H. Asimple method of estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
22. Conkle J.L., Lattao C.V., White J.R., Cook R.L. Pharmaceutical analysis for environmental samples: individual and simultaneous determination of ciprofloxacin, ofloxacin and norfloxacin using an HPLC with fluorescence and UV detection with a wetland soil matrix. Analytic Lett 2009, 42:2937-2950.
23. Sher M., Hussain M.A., Mehmood M.H., Hassan M.N., Bashir S. Bioequivalence of norfloxacin by HPLC-UV method. JChil Chem Soc 2010, 55:203-205.
24. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard - 8th edition: Approved Standard M7-A8 2009, Clinical and Laboratory Standards Institute, CLSI, Wayne, PA, USA.
25. Valgas C., Machado de Souza S., Smânia E.F.A., Smânia A. Screening methods to determine antibacterial activity of natural products. Braz J Microbiol 2007, 38:369-380.
26. Bonev B., Hooper J., Parisot J. Principles of assessing bacterial susceptibility to antibiotics using the agar diffusion method. JAntimicrob Chemother 2008, 61:1295-1301.
27. Fernandez J., Hilliard J.J., Morrow B.J., Melton J.L., Flamm L.K., Barron A.M., et al. Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections. Antimicrob Agents Chemother 2011, 55:5522-5528.
28. Chamberlain G., Fox J., Ashton B., Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007, 25:2739-2749.
29. Meran L, Rashidi H, Jones R, Rose F, Shakesheff K, HawkeyC. Abstract of the 7th Congress of ECCO: the European Crohn's and Colitis Organisation, 2012 Barcelona. Abstract vol. 6, p. S23. Drugs used in the treatment of fistulae in Crohn's disease preserve mesenchymal stem cell survival.
30. Ip J.E., Wu Y., Huang J., Zhang L.N., Pratt R.E., Dzau V.J. Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell 2007, 18:2873-2882.
31. Rüster B., Göttig S., Ludwig R.J., Bistrian R., Müller S., Seifried E., et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006, 108:3938-3944.
32. Kumar S., Ponnazhagan S. Bone homing of mesenchymal stem cells by ectopic α4 integrin expression. FASEB J 2007, 21:3917-3927.
33. Loebinger M.R., Sage E.K., Janes S.M. Mesenchymal stem cells as vectors for lung disease. Proc Am Thorac Soc 2008, 5:711-716.
34. Krasnodembskaya A., Song Serikov V., Lee J.W., Matthay M.A. Anti- bacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010, 28:2229-2238.
35. Mei S.H., Haitsma J.J., Dos Santos C.C., Deng Y., Lai P.F., Slutsky A.S., et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010, 182:1047-1057.
36. Lee J.W., Krasnodembskaya A., McKenna D.H., Song Y., Abbott J., Matthay M.A. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013, 187:751-760.
37. DelaRosa O., Lombardo E. Modulation of adult mesenchymal stem cells activity by Toll-like receptors: implications on therapeutic potential. Mediat Inflamm 2010, 10.1155/2010/865601.
38. Schaffler A., Buchler C. Concise review: adipose tissue derived stromal cell-basic and clinical implications for novel cell-based therapies. Stem Cells 2007, 25:818-827.